/
INVA
$23.14-$0.43 (-1.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
74M shares
52-week range
$16.52 – $25.15
77% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$9.73
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $261.0M | $261.0M | $336.8M | $391.9M | $331.3M | $310.5M | $358.7M | $425.1M |
| Cost of revenue | $0 | $0 | $0 | $0 | $13.8M | $42.6M | $36.6M | $117.6M |
| Gross profit | $261.0M | $261.0M | $336.8M | $391.9M | $317.5M | $267.8M | $322.1M | $307.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.8% | 86.3% | 89.8% | 72.3% |
| R&D | $0 | $0 | $1.8M | $576.0K | $41.4M | $33.9M | $13.7M | $30.6M |
| Operating income | $238.3M | $246.4M | $321.1M | $375.1M | $207.0M | $113.9M | $166.9M | $163.7M |
| EBITDA | $248.1M | $260.2M | $372.6M | $478.2M | $308.3M | $235.0M | $85.5M | $383.8M |
| Net income | $395.1M | $157.3M | $224.4M | $265.9M | $213.9M | $179.7M | $23.4M | $271.2M |
| Net margin | 151.4% | 60.3% | 66.6% | 67.8% | 64.6% | 57.9% | 6.5% | 63.8% |
| EPS (diluted) | 3.53 | 1.43 | 2.02 | 2.87 | 2.37 | 2.20 | 0.36 | 3.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $441M | $3.57 | $3.41–$3.70 | 2 |
| 2027 | $484M | $2.24 | $2.14–$2.32 | 2 |
| 2028 | $512M | $2.05 | $1.76–$2.34 | 2 |
| 2029 | $569M | $1.89 | $1.81–$1.96 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$65.87
Price
$23.14
Implied upside
+185%
Peer comparison
Innoviva, Inc. Common Stock
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
www.inva.com- Employees
- 159
- IPO / List date
- Oct 5, 2004
- HQ
- BURLINGAME, CA
Held by traders on TradeandTell
No one on the platform currently holds INVA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 4,055,632 | $94.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-06-17 | 1-for-100reverse |
Recent trades on TradeandTell
No one on the platform has traded INVA yet.
